Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in brachytherapy utilization in Canada from 2011 to 2020.

Physics and imaging in radiation oncology·2026
Same author

B-cell precursor acute lymphoblastic leukaemia with <i>IGH::CEBP</i> rearrangement: what have we learnt over the years?

Haematologica·2026
Same author

Evaluating the Role of VELscope in Oral Cancer and Pre-Cancer Screening: A Scoping Review.

Asian Pacific journal of cancer prevention : APJCP·2026
Same author

Towards robust deep learning-based autosegmentation in MRI-planned gynecological brachytherapy: Importance of scalable development and comprehensive evaluation.

Brachytherapy·2026
Same author

Benchmarking the paediatric T-cell ALL subtype classifier, TALLSorts.

British journal of haematology·2025
Same author

Neonatal unit human resources: coverage for six cadres and trends for staff-to-baby ratios in 65 neonatal units implementing with NEST360 in Kenya, Malawi, Nigeria, and Tanzania.

Human resources for health·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Burkitt's lymphoma.

Elizabeth M Molyneux1, Rosemary Rochford, Beverly Griffin

  • 1College Of Medicine, Blantyre, Malawi. emolyneux@malawi.net

Lancet (London, England)
|February 16, 2012
PubMed
Summary
This summary is machine-generated.

Burkitt's lymphoma, a fast-growing cancer, is linked to Epstein-Barr virus and c-MYC oncogene activation. Treatment success varies by age and location, with promising future therapies like rituximab.

More Related Videos

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Related Experiment Videos

Last Updated: May 24, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Area of Science:

  • Oncology
  • Hematology
  • Virology

Background:

  • Burkitt's lymphoma is an aggressive B-cell non-Hodgkin lymphoma, characterized by rapid tumor growth.
  • It is associated with Epstein-Barr virus and chromosomal translocations activating the c-MYC oncogene.
  • This lymphoma is the most common childhood cancer in malaria-endemic regions and prevalent in HIV-infected individuals.

Purpose of the Study:

  • To review the characteristics, associations, and treatment outcomes of Burkitt's lymphoma.
  • To highlight disparities in treatment and outcomes based on patient age and geographic location.
  • To explore potential advancements in therapy, including monoclonal antibody treatment.

Main Methods:

  • Literature review of Burkitt's lymphoma epidemiology, pathogenesis, and clinical management.
  • Analysis of treatment outcomes in different patient populations (children vs. adults) and healthcare settings (low-income vs. high-income countries).
  • Evaluation of emerging therapeutic strategies, such as rituximab.

Main Results:

  • Outcomes for Burkitt's lymphoma are excellent in children with intensive chemotherapy but poor in elderly adults.
  • Treatment intensity and success rates differ significantly between low-income and high-income countries.
  • Rituximab shows potential for improving outcomes and reducing toxicity.

Conclusions:

  • Burkitt's lymphoma management requires intensive chemotherapy and robust supportive care.
  • Age and socioeconomic factors critically influence treatment success.
  • Monoclonal antibody therapy represents a promising future direction for improving patient prognosis.